Sign In
Buy ARQT
$21.35
+0.560 (+2.69%)
At Close: Jun 03, 2026
Arcutis (ARQT) Files sNDA for Zoryve in Atopic Dermatitis, Stock Up
09:46am, Wednesday, 13'th Sep 2023
Arcutis (ARQT) submits sNDA, seeking label expansion of Zoryve (roflumilast) cream 0.15% to treat patients with atopic dermatitis.
Why Shares of Arcutis Biotherapeutics Fell This Week
03:08pm, Thursday, 07'th Sep 2023
Arcutis' cash position is the biggest concern for investors. The company is already seeing strong sales from Zoryve, a little more than a year after it was launched.
Arcutis to Present at Upcoming Investor Conference
04:00pm, Tuesday, 05'th Sep 2023
WESTLAKE VILLAGE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-de
3 Biotech Stocks Due for a Massive Short Squeeze
10:33am, Thursday, 31'st Aug 2023
Here's a look at 3 biotech short squeeze candidates. For investors looking for short-term gains, technical analysis provides key insights on potential entry and exit points.
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Tops Revenue Estimates
07:41pm, Tuesday, 08'th Aug 2023
Arcutis Biotherapeutics, Inc. (ARQT) came out with a quarterly loss of $1.16 per share versus the Zacks Consensus Estimate of a loss of $1.22. This compares to loss of $1.31 per share a year ago.
Arcutis to Report Second Quarter Financial Results
04:00pm, Monday, 24'th Jul 2023
WESTLAKE VILLAGE, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovat
Why Shares of Arcutis Biotherapeutics Jumped This Week
05:33pm, Friday, 09'th Jun 2023
Arcutis Biotherapeutics launched roflumilast in a cream form last summer to treat plaque psoriasis. The company anticipates launching the therapy in a foam early next year.
Arcutis to Present at Upcoming Investor Conference
04:00pm, Tuesday, 06'th Jun 2023
WESTLAKE VILLAGE, Calif., June 06, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-der
7 Short-Interest Stocks to Target for Explosive Gains
04:37pm, Thursday, 18'th May 2023
Ranking among the most speculative practices in the equities arena, deliberately bidding up short-interest stocks may generate wildly robust gains. At the same time, higher risks for the intrepid mark
Arcutis Biotherapeutics, Inc. (ARQT) Q1 2023 Earnings Call Transcript
07:53pm, Saturday, 13'th May 2023
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT ) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Eric McIntyre - Head of Investor Relations Frank Watanabe - President & Chief E
Arcutis to Report First Quarter Financial Results
04:00pm, Tuesday, 25'th Apr 2023
WESTLAKE VILLAGE, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innova
Arcutis to Present at Upcoming Investor Conference
04:45pm, Wednesday, 12'th Apr 2023
WESTLAKE VILLAGE, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-der
WESTLAKE VILLAGE, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage company focused on developing meaningful innovations in immuno-de
Arcutis Biotherapeutics, Inc. (ARQT) Q4 2022 Earnings Call Transcript
11:12pm, Tuesday, 28'th Feb 2023
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT ) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET Company Participants Eric McIntyre - Head of Investor Relations Frank Watanabe - President &
Arcutis Biotherapeutics: Market Discounting Zoryve Momentum
04:56am, Thursday, 09'th Feb 2023
The market has discounted momentum around Arcutis' Zoryve label. This looks overdone and investors appear to have overlooked the additional data points surrounding the segment.
